Citi Assesses Daiichi's Supply Review as Immaterial for AstraZeneca
Citi has stated that Daiichi Sankyo's decision to delay its full-year 2025 results does not pose a material risk to AstraZeneca. The delay is attributed to Daiichi's internal manufacturing review, and Citi maintains a 'buy' rating on AstraZeneca's stock, citing no expected impact on drug sales.
Topics: financial analysis partnership pharmaceuticals stock rating supply chain